1999
Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma
Diamandis E, Helle S, Yu H, Melegos D, Lundgren S, Lonning P. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. Cancer 1999, 85: 891-898. PMID: 10091767, DOI: 10.1002/(sici)1097-0142(19990215)85:4<891::aid-cncr17>3.0.co;2-k.Peer-Reviewed Original ResearchConceptsPlasma prostate-specific antigenProstate-specific antigenPlasma PSA levelsMetastatic breast carcinomaMegestrol acetatePSA levelsPSA increaseMA treatmentPrognostic valueBreast carcinomaSpecific antigenSecretion of PSAMegestrol acetate treatmentPlasma PSA concentrationProgestin megestrol acetateSensitive immunofluorometric procedureSerial plasma levelsSubset of patientsOverall patient survivalRisk of deathMA withdrawalAlternative regimensPSA changeBetter prognosisDistant metastasis
1997
Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l
Yu H, Diamandis E, Wong P, Nam R, Trachtenberg J. Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l. Journal Of Urology 1997, 157: 913-918.. DOI: 10.1097/00005392-199703000-00047.Peer-Reviewed Original ResearchProstate-specific antigenPositive surgical marginsPreoperative prostate-specific antigenSerum prostate-specific antigenSerial serum samplesBiochemical relapseMicro g.Clinicopathological featuresSurgical marginsRadical prostatectomyTumor volumeLogistic regression modelsPSA changeGreater preoperative prostate specific antigenPostoperative serum prostate-specific antigenHigher preoperative prostate-specific antigenPostoperative prostate-specific antigenUnconditional logistic regression modelsSerum samplesProstate-specific antigen monitoringSerum PSA changesUnivariate logistic regression modelYear of surgerySubset of patientsLength of followupDetection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l
Yu H, Diamandis E, Wong P, Nam R, Trachtenberg J. Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l. Journal Of Urology 1997, 157: 913-918. PMID: 9072598, DOI: 10.1016/s0022-5347(01)65082-1.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPositive surgical marginsPreoperative prostate-specific antigenSerum prostate-specific antigenSerial serum samplesBiochemical relapseSurgical marginsClinicopathological featuresRadical prostatectomyTumor volumeLogistic regression modelsPSA changeGreater preoperative prostate specific antigenPostoperative serum prostate-specific antigenHigher preoperative prostate-specific antigenPostoperative prostate-specific antigenUnconditional logistic regression modelsSerum samplesProstate-specific antigen monitoringSerum PSA changesSubset of patientsUnivariate logistic regression modelYear of surgeryLength of followupConventional prostate specific antigen
1996
Circulating antibodies against p53 protein in patients with ovarian carcinoma
Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis E. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Cancer 1996, 78: 2146-2152. PMID: 8918407, DOI: 10.1002/(sici)1097-0142(19961115)78:10<2146::aid-cncr15>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsAntibody-positive patientsOvarian carcinomaP53 antibodiesP53 autoantibodiesPositive patientsSuch antibodiesMultivariate analysisPatient disease-free survivalKaplan-Meier survival curvesSerum p53 antibodiesTumor p53 overexpressionDisease-free survivalOlder patient ageSubset of patientsTumor histologic typeOverall patient survivalSera of patientsFrequent molecular eventUnits/LFree survivalNegative patientsOverall survivalPatient ageSuch autoantibodiesAntibody levels
1995
Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma
Levesque M, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis E. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995, 75: 1327-1338. PMID: 7882283, DOI: 10.1002/1097-0142(19950315)75:6<1327::aid-cncr2820750615>3.0.co;2-p.Peer-Reviewed Original ResearchConceptsEpithelial ovarian carcinomaOvarian carcinomaMutant p53 proteinResidual tumorHistologic gradeOvarian cancerP53 proteinCancer relapseMutant p53 protein overexpressionLonger disease-free survivalKaplan-Meier survival curvesPostsurgical residual tumorDisease-free survivalEarly-stage diseaseSubset of patientsLow histologic gradeMutant p53 protein accumulationAdvanced-stage cancerDifferent clinical stagesP53-negative tumorsP53-positive tumorsP53 protein overexpressionPoor patient outcomesAnti-p53 antibodiesP53 protein accumulation